Nutritional Therapy in Late-onset Pompe Disease
- Conditions
- Pompe DiseaseLysosomal Storage DiseasesNutrition PoorGlycogen Storage Disease Type II Late OnsetGlycogen Storage Disease Type II, AdultMuscle LossGlycogen Storage Disease Type IIObesity
- Interventions
- Dietary Supplement: Placebo (PLA)Dietary Supplement: Multi-ingredient supplement (PDT-MIS)
- Registration Number
- NCT06130228
- Lead Sponsor
- McMaster University
- Brief Summary
RATIONALE: Pompe disease (PD) is a recessive genetic disorder wherein the body cannot break down glycogen due to a mutation in the acid alpha glucosidase (GAA) gene, which encodes for acid alpha-glucosidase. The adult/late onset form (LOPD) leads to glycogen accumulation and autophagic buildup, causing progressive muscle weakness that leads to wheelchair dependence, reduced quality of life and premature death due to cardiorespiratory insufficiency. While nutritional strategies, such as the low carbohydrate/high protein and ketogenic diets, have been used clinically, they are difficult to maintain and have limited benefits. Multi-ingredient supplementation (MIS) allows for targeting of several underlying pathogenic pathways and may be more convenient than traditional dietary strategies, thereby improving both adherence and LOPD pathology.
- Detailed Description
DESIGN AND INTERVENTION: The present study is a 4-month randomized, double-blind, placebo-controlled clinical trial (RCT) with sampling pre and post intervention in late onset Pompe disease patients undergoing enzyme replacement therapy (ERT) (21-90 years of age). Each patient will be randomized into either a Pompe-Targeted Multi-Ingredient Supplement (PDT-MIS; high-quality proteins, antioxidants, plant extracts, vitamins, and omega-3 fatty acids,) or placebo (PLA; collagen, safflower, and cellulose) group and then undergo four months of daily supplementation with concurrent rehabilitative exercise training (mixed cardio and strength four days/week) and respiratory muscle training (four days/week).
GENERAL RESEARCH AIMS AND HYPOTHESIS: The purpose of this study is to investigate the benefits of PDT-MIS on muscle and blood pathology, muscle function, respiratory capacity, and health-related quality of life (HRQOL) in LOPD patients on enzyme replacement therapy (ERT). It is generally hypothesized that PTD-MIS will mitigate mitochondrial dysfunction, oxidative damage, inflammation and alleviate 'autophagic block' in skeletal muscle of LOPD patients. PDT-MIS may therefore improve muscle pathology by affecting several cell pathways simultaneously, and thereby enhance muscle function, respiratory capacity, and HRQOL of LOPD patients.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 28
- Genetically confirmed LOPD
- Have undergone enzyme replacement therapy for at least three months.
- Physically capable of doing rehabilitative exercise, respiratory muscle training, and the clinical tests described herein.
- Dairy protein allergy
- Renal disease (creatinine > 140)
- Attempting pregnancy or currently pregnant
- Current supplementation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo (PLA) Placebo (PLA) Placebo (PLA) consists of daily intake of collagen, safflower, and microcrystalline cellulose. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week. Multi-ingredient supplement (PDT-MIS) Multi-ingredient supplement (PDT-MIS) Multi-ingredient supplementation (PDT-MIS) consists of daily intake of high-quality proteins, creatine, vitamin D, calcium, plant extracts (green coffee bean, green tea, beet root, and forskolin), and Omega-3 fatty acids. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week.
- Primary Outcome Measures
Name Time Method Percent change in seated pulmonary function by spirometry Baseline to 4 months Seated forced expiratory volume/forced vital capacity ratio (FEV1/FVC)
Percent change in the body composition index by DEXA analyses Baseline to 4 months Body composition index (lean mass/fat mass ratio)
Percent change in supine pulmonary function by spirometry Baseline to 4 months Supine forced expiratory volume/forced vital capacity ratio (FEV1/FVC)
Percent change in 6-minute walking test distance Baseline to 4 months 6-minute walking test distance (meters)
- Secondary Outcome Measures
Name Time Method Percent change in leg strength by 4-step stair climb test Baseline to 4 months 4-step stair climb time (seconds)
Percent change in lysosomal glycogen in muscle by high-resolution light microscopy Baseline to 4 months Lysosomal glycogen (% total muscle area)
Percent change in galactin-3 expression in muscle by Western blotting Baseline to 4 months Galactin-3 expression (optical density)
Percent change in health-related quality of life by the R-Pact Questionnaire Baseline to 4 months Rasch-built Pompe-specific Activity (ranging from low 0 to high 100 points)
Percent change in maximal grip strength by dynamometry Baseline to 4 months Maximal grip strength (kilogram)
Percent change in health-related quality of life by Rotterdam Handicap Score Baseline to 4 months Rotterdam Handicap Score (ranging from low 9 to high 36)
Percent change in isometric leg strength by Biodex Baseline to 4 months Isometric leg strength (newton meters)
Percent change in lower extremity functioning by timed get up and go test (TUG) Baseline to 4 months Timed get up and go test (seconds)
Percent change in autophagic area in muscle by electron microscopy Baseline to 4 months Autopgahic area (% total muscle area)
Percent change in complex I-V expression in muscle by Western blotting Baseline to 4 months Complex I-V expression (optical density)
Percent change in health-related quality of life by SF-36 Survey Baseline to 4 months 36-item short form survey (ranging from low 0 to high 100)
Percent change in lower extremity functioning by short physical performance battery (SPPB) Baseline to 4 months Short physical performance battery (ranging from low 0 to high 12)
Percent change in total muscle glycogen by ELISA Baseline to 4 months Total muscle glycogen (ug per mg of tissue)
Percent change in 4-hydroxynonenal levels in muscle by Western blotting Baseline to 4 months 4-hydroxynonenal levels (optical density)
Percent change in superoxide dismutase 1 expression in muscle by Western blotting Baseline to 4 months Superoxide dismutase 1 expression (optical density)
Percent change in p62 expression in muscle by Western blotting Baseline to 4 months p62 expression (optical density)
Percent change in superoxide dismutase 2 expression in muscle by Western blotting Baseline to 4 months Superoxide dismutase 2 expression (optical density)